Introduction
This report provides a detailed analysis of Anixa Biosciences, Inc. (ANIX), a $104.48 M company, operating in the Biotechnology industry. The core questions for investors is whether the current stock price represents a fair value and if the company is well-positioned for future growth. Would it be wise to invest in Anixa Biosciences, Inc. at this moment? Let’s see how well ANIX stock performs in the current market.
Here’s What You Need to Know Right Now
The stock is currently trading at $3.31 (as of June 2025), and it’s showing positive momentum, trading above both its 50-day and 200-day moving averages.
Analysts are cautious, with a 1-year price target of $9.00 (a potential -37.0% downside). However, there’s significant volatility here (87.3% annualized), suggesting the potential for wide price swings.
Anixa Biosciences, Inc.’s fundamental story is nuanced. On one hand, the company benefits from a portfolio of established brands. On the other, it faces challenges with intense competition in its sector.
What’s Inside This Analysis?
We’re not just throwing numbers at you—we’re breaking down ANIX’s stock from every angle so you can make an informed decision:
- ✅ Is now a good time to buy?
Technicals say, “Neutral” (but RSI is neutral at 46.4).
Fundamentals say, “be cautious” (driven by debt levels and growth metrics). - ✅ Can its core operations drive future growth?
Future growth will likely depend on performance in its core Biotechnology operations and ability to manage competitive pressures. - ✅ What are the biggest risks?
The company carries $221.00 K in debt, which could be a headwind in a high-interest-rate environment.
Competition is fierce from both established players and new entrants.
Most stock analyses either use hard-to-understand jargon or say something too simple like “just buy” and trust the outcome. This is not what’s happening. We’re here with clear information that benefits you, no matter if you invest for long-term results or try for fast profits.
All in all, is Anixa Biosciences, Inc. the right investment to make sure your money tells a story of success and satisfaction? Or is there underlying issues to be wary of? Stick around as we get to the details in the data.
Metrics Summary
💰 Current Price
🎯 Price Targets & Forecasts
📉 -25.3%
📉 -37.0%
📈 +171.9%
📈 Trend & Momentum
🚀 ▲ Bullish (Price > SMA 50/200)
46.4 (Neutral) ⚖️
➡️ Neutral Trend (-0.04)
📊 Key Technical Levels
✅ $2.91
✅ $2.82
📏 $2.07 – $4.20
⚡ Volatility
87.3% 🌪️
0.33xx 🛡️
(Low Sensitivity)
7/30 (23%) 🔴
🏢 Ownership
17.60% 🏠
1.27% 😊
(Low Bearish Bets)
Right now, ANIX’s stock is trading at $3.31. The technical indicators are showing a bullish pattern because the price is holding relative to both the 50-day ($2.91) and 200-day ($2.82) moving averages. This suggests the stock has been gaining momentum recently. However, the Relative Strength Index (RSI) at 46.4 is Neutral—neither overbought nor oversold—while the MACD indicator shows a neutral trend, meaning there could be some minor pullbacks before the next upward move.
Over the past year, ANIX’s stock has traded between $2.07 and $4.20, which tells us two things: First, investor sentiment has been mixed. Second, the current price is trading mid-range, meaning big swings are less likely unless something major happens. Analysts expect modest growth ahead, with a 1-year target of $2.09 (-37.0%) and an average consensus target of $9.00 (+171.9%). Plus, with 17.60% institutional ownership and very low short interest (1.27% (Low Bearish Bets)), it seems most big investors are betting on the company’s long-term success rather than a decline.
Detailed Forecast Table
The detailed monthy forecast below outlines the model’s expectations for ANIX’s price evolution ($0.15 to $4.79). It includes projected ranges (Min, Avg, Max), potential ROI based on the average projection versus the current price, and a derived model signal for each period.
Over the forecast horizon (2025-06 to 2026-06), ANIX’s price is projected by the model to fluctuate between approximately $0.15 and $4.79.
The projected price range remains relatively consistent (from $3.24 – $3.24 to $0.25 – $3.92), implying stable forecast uncertainty.
Month (Period) | Min. Price | Avg. Price | Max. Price | Potential ROI vs Current ($3.31) | Model Signal |
---|---|---|---|---|---|
2025-06 | $3.24 | $3.24 | $3.24 | ▼ -2.2% | Hold/Neutral |
2025-07 | $0.39 | $2.56 | $4.78 | ▼ -22.6% | Consider Short |
2025-08 | $0.22 | $2.47 | $4.50 | ▼ -25.3% | Consider Short |
2025-09 | $0.35 | $2.47 | $4.63 | ▼ -25.3% | Consider Short |
2025-10 | $1.17 | $2.55 | $4.19 | ▼ -22.9% | Consider Short |
2025-11 | $0.68 | $2.43 | $3.83 | ▼ -26.5% | Consider Short |
2025-12 | $0.40 | $2.27 | $4.22 | ▼ -31.3% | Consider Short |
2026-01 | $0.15 | $2.18 | $4.79 | ▼ -34.1% | Consider Short |
2026-02 | $0.41 | $2.23 | $3.85 | ▼ -32.6% | Consider Short |
2026-03 | $0.66 | $2.25 | $4.21 | ▼ -31.9% | Consider Short |
2026-04 | $0.28 | $2.19 | $3.98 | ▼ -33.8% | Consider Short |
2026-05 | $0.33 | $2.10 | $3.74 | ▼ -36.5% | Consider Short |
2026-06 | $0.25 | $2.09 | $3.92 | ▼ -37.0% | Consider Short |
Remember that these forecasts are generated by models, carry inherent uncertainty, and can change with new data or market shifts. Future prices are not guaranteed.
Total Valuation
While Anixa Biosciences, Inc. has a market cap of $104.48 M, its enterprise value of $89.10 M is lower, reflecting a strong net cash position of approximately $15.38M. This financial strength provides a cushion and flexibility for future investments.
The upcoming 2025-05-28 earnings report will be crucial in showing whether Anixa Biosciences, Inc.’s businesses can grow into this valuation. Essentially, you’re paying for quality – but quality doesn’t come cheap.
Market Cap | $104.48 M |
Enterprise Value | $89.10 M |
Next Earnings Date | 2025-05-28 |
Profitability Growth
An analysis of the key metrics in ANIX’s margin performance suggests the company faces significant margin pressure. The company is successful in controlling its production costs, as shown by the gross margin of 0.00%, and it also profits well from its core operations, reflected in the 0.00% operating margin. A 0.00% EBITDA margin indicates ANIX is capable of generating strong cash flow from its operations before accounting for financing and tax strategies. All things considered, ANIX can hold onto around $0.000 in net profit for every $1 of its revenue over the last twelve months.
ANIX’s N/A in EBITDA and N/A in gross profit indicate its raw earning power, while the $-12.13 M in net income reveals how effectively it converts that power into bottom-line results. In the future, maintaining steady or improving margins will be critical. ANIX needs to defend its pricing power and control operating costs, as this will help sustain profitability, especially if revenue growth moderates.
Profit Margin (TTM) | 0.00% |
Operating Margin (TTM) | 0.00% |
Gross Margin (TTM) | 0.00% |
EBITDA Margin (TTM) | 0.00% |
Net Income (TTM) | $-12.13 M |
Analyst Insights
This section summarizes the collective view of professional analysts covering ANIX. The consensus recommendation is ‘Buy’. This consensus is based on opinions from 3 analysts(s). The mean price target is $9.00, with individual targets ranging from $7.00 – $10.00. Based on the mean target ($9.00), this implies a potential upside of ~171.9% from the current price ($3.31). This provides a gauge of Wall Street sentiment regarding the stock’s potential.
Technical Analysis Summary
Current Price: $3.31 | Trend: Bullish but shows signs of slowing
The stock has faced downward pressure, losing -5.16% in the last 15 days. We need to analyze the technicals to see if this is a buying opportunity or a warning of further declines. Let’s break down the key levels.
1. Trend Strength – Still Bullish
ANIX is trading above its key moving averages, which confirms the uptrend remains intact. The 20-day SMA at $3.35 is acting as immediate dynamic support.
What This Means for Traders?
As long as ANIX holds above the 20-day SMA ($3.35), the bullish momentum could continue. However, a rapid rise can push the stock far from its averages, increasing the risk of a pullback.
2. Momentum Check – Is Momentum Fading?
The RSI at 46.4 is in a neutral zone, indicating balanced momentum. At the same time, the MACD histogram is negative, suggesting that the upward momentum is beginning to fade.
Trading Strategy:
This neutral RSI reading provides flexibility. Watch for a decisive MACD crossover or a break of a key support/resistance level for the next directional clue.
3. Bollinger Bands – Testing Key Levels
The stock is trading near the middle of its Bollinger Bands (SMA20: $3.35), with the lower band at $2.79 offering the next level of support.
Key Levels to Watch:
- Resistance: $3.80 (Recent High) → A breakout could push ANIX higher.
- Support: $3.35 (20-day SMA) → If this breaks, expect a test of $2.79.
4. Volume Trends – Checking for Conviction
Trading volume is near its recent average, providing neutral confirmation of the current price action.
What’s the Concern?
Low volume rallies are prone to sharp reversals. If we don’t see a surge in buying interest to confirm the move, a pullback becomes more likely.
5. Support & Resistance – The Trading Plan
Trading Plan:
- ✅ If ANIX holds above $3.35 → Bullish trend continues, next target $3.80.
- ⚠️ If it breaks below $3.35 → Expect a dip toward $2.79.
- 🛑 A drop below $2.79 → Could trigger a deeper correction to the 200-day SMA ($2.82).
Final Verdict – Should You Buy, Hold, or Sell?
Bottom Line: The technicals suggest the rally may be running out of steam short-term. While the long-term trend remains bullish, a correction seems plausible before the next major move. Trade carefully and wait for confirmation at key levels.
Short Selling Info
There is currently $401 K worth of short interest in ANIX, and the short ratio (or days to cover) is 2.1x. This means that at the stock’s recent average trading volume, it would take around 2 days for all short positions to be covered. This low level suggests that short sellers do not currently have significant control over the stock’s price, and the risk of a prolonged ‘short squeeze’ is relatively low.
With 1.27% of the public float sold short, a very low percentage of the available shares are being shorted, indicating a general lack of bearish sentiment among investors. This level has increased recently from $377 K, suggesting a shift in bearish sentiment. Because the amount of investors shorting is generally low, the market tends to feel more confident and the risks of price swings from sudden short-covering activities are reduced.
Shares Short | $401 K |
Short Ratio (Days To Cover) | 2.10x |
Short % of Float | 1.27% |
Shares Short (Prior Month) | $377 K |
Short Date | 2025-06-13 |
Stock Price Statistics
When looking at the price range over the past year, the stock has seen a high of $4.20 and a low of $2.07. This wide gap tells us the stock has been through significant fluctuations, likely influenced by market sentiment or company-specific news. Currently, the 50-day moving average at $2.91 is slightly above the 200-day moving average of $2.82. This ‘golden cross’ setup is often viewed as a bullish signal, indicating positive long-term momentum.
With a beta of 0.33x, the stock tends to be less volatile than the broader market, moving about 67% less. Combined with a high 30-day annualized volatility of 87.3%, it’s clear this stock sees frequent price swings. For investors, this means potential for gains, but also higher downside risk. These indicators matter when deciding position sizing or entry timing, especially if you’re managing a portfolio that balances stability with growth exposure.
52 Week High | $4.20 |
52 Week Low | $2.07 |
50 Day MA | $2.92 |
200 Day MA | $2.97 |
Beta | 0.33x |
Volatility (30d Ann.) | 87.3% 📉 |
Conclusion Outlook
Short-Term Technical Snapshot
- ▲Overall Technical Sentiment: Neutral-Bullish
- ▲Price Trend vs MAs: bullish (above SMA50/200)
- ●Momentum (RSI): Neutral (46.4)
- 📊Support / Resistance (30d): ~$2.46 / ~$3.80
Longer-Term Fundamental & Forecast Outlook
- ▼1-Year Avg. Forecast: ~-37.0% avg. change to ≈$2.09
- ●Fundamental Health: Assessment Incomplete (ROE: -65.38%, D/E: 1.48x)
- ●Valuation Snapshot: Appears Moderate (Fwd P/E: -9.01x)
- ●Recent Growth (YoY): N/A (Rev: N/A, Earn: N/A)
- ▲Analyst Consensus: Buy (Target: $9.00)
Overall Assessment & Outlook
Synthesizing the data, ANIX currently shows Neutral-Bullish technicals coupled with moderate fundamentals. From a valuation standpoint, it looks Appears Moderate (Fwd P/E: -9.01x). Models project a 1-year path indicating potential downside (-37.0%), targeting ≈$2.09. Decision-making should factor in these elements against identified risks and their individual investment horizon.
Important: This analysis synthesizes model outputs and publicly available data for informational purposes only. It is not investment advice. Market conditions change rapidly. Always conduct thorough independent research and consult a qualified financial advisor before making investment decisions.
Risk Factors
Potential investors in ANIX should be aware of several risk factors. The following list highlights key considerations based on data and market dynamics, but may not include all possible risks.
- ⚠️ High Volatility: Recent annualized volatility (87.3%) suggests significant price swings.
- ⚠️ Overall market fluctuations can impact the stock.
- ⚠️ Factors specific to the Biotechnology industry or Healthcare sector can affect performance.
- ⚠️ Changes in macroeconomic conditions (interest rates, inflation) pose risks.
- ⚠️ Unforeseen company events or news can impact the price.